all report title image
  • Published On : Feb 2022
  • Code : CMI4909
  • Industry : Pharmaceutical
  • Pages : 207
  • Formats :

Eosinophilic esophagitis (EoE) is a chronic immune system disease of the esophagus. In EoE, a large number of white blood cells called eosinophils are found in the inner lining of the esophagus. This buildup, which is a reaction to food, allergen, or acid reflux, can inflame or injure the esophageal tissue. Difficulties in swallowing, impaction, chest pain often centrally located that does not respond to antacids, and the backflow of undigested food are the signs and symptoms of eosinophilic esophagitis in adults.

The global eosinophilic esophagitis market is estimated to be valued at US$ 138.4 million in 2021 and is expected to exhibit a CAGR of 33.3% during the forecast period (2021-2028).

Figure 1. Global Eosinophilic Esophagitis Market in Terms of Value (US$ million), By Region, 2021

Eosinophilic Esophagitis  | Coherent Market Insights

Promising results for potential drug candidates are estimated to drive the global eosinophilic esophagitis market growth during the forecast period.

  • Drug candidates which are developed and investigated for the treatment of eosinophilic esophagitis have shown promising results in clinical trials. As a result, regulatory authorities such as the U.S. Food and Drug Administration (FDA) are awarding designations to these drug candidates. This is expected to augment the market growth over the forecast period. For instance, in February 2021, Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced that the company received Fast Track designation from the U.S. FDA for the treatment of Eosinophilic Esophagitis (EoE), a rare, chronic allergic inflammatory disease characterized by eosinophilic infiltration of the esophagus.
CMI table icon

Eosinophilic Esophagitis Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 138.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 33.3% 2028 Value Projection: US$ 1,037.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Corticosteroids (Budesonide (Jorveza, Off-label budesonide), Fluticasone), Proton Pump Inhibitor (PPI) (Omeprazole, Esomeprazole, Others), Late Stage Pipeline Drugs (Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, Omilancor (BT-11)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH

Growth Drivers:
  • Promising Results for Potential Drug Candidates
  • Increasing Awareness Programs for Eosinophil-associated disorders
Restraints & Challenges:
  • Stringent Regulations for Drug Approval

Figure 2.Global Eosinophilic Esophagitis Market Share (%), By Drug Class, 2021

Eosinophilic Esophagitis  | Coherent Market Insights

Increasing awareness programs for Eosinophil-associated disorders is anticipated to propel the global eosinophilic esophagitis market growth over the forecast period.

Various awareness programs have been developed and implemented to educate the public and medical community about eosinophil-associated disorders which is anticipated to drive the market growth over the forecast period. The American Partnership for Eosinophilic Disorders (APFED), a nonprofit organization, was founded in December 2001, which works on educating, raising awareness, supporting, and advocating for patients and families who are suffering from eosinophil-associated diseases.

Global Eosinophilic Esophagitis Market – Impact of Coronavirus (COVID-19) Pandemic

  • The coronavirus (COVID-19) pandemic was first reported on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. A number of research have been carried out to depict the relation between the COVID-19 and eosinophilic esophagitis (EoE). Furthermore, research has been underway in which researchers are finding the correlation of mortality in patients due to the COVID-19 and eosinophilic esophagitis.
  • According to the European Journal of Gastroenterology and Hepatology: December 2020, several studies have been carried out that explain different phenotypes and endotypes of EoE which exist all over the world. Moreover, a subset of EoE is characterized by Th2-predominant inflammation (Th2-high EoE endotype) and positively associated with other allergic diseases such as atopic dermatitis, allergic rhinitis, food allergies, and type-2 high asthma.

Global Eosinophilic Esophagitis Market: Restraints

As of now, no specific treatment has been approved for eosinophilic esophagitis in the U.S. Market players are focusing on developing drug candidates for the treatment of EoE. However, there are many challenges associated with obtaining approval from the regulatory authorities which is anticipated to hinder the market growth over the forecast period. Obtaining approval for the drug from regulatory authorities is a tedious and challenging as regulatory authorities such as the U.S. Food and Drug Administration (FDA) impose substantial and burdensome requirements upon companies involved in the clinical development, manufacturing, marketing, and distribution of drugs

Key Players

Major players operating in the global eosinophilic esophagitis market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2023. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

  • This report provides an in-depth analysis of the global eosinophilic esophagitis market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global eosinophilic esophagitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis

Detailed Segmentation:

  • Global Eosinophilic Esophagitis Market, By Drug Class:
    • Corticosteroids
      • Budesonide
        • Jorveza
        • Off-label budesonide
      • Fluticasone
    • Proton Pump Inhibitor (PPI)
      • Omeprazole
      • Esomeprazole
      • Others
    • Late Stage Pipeline Drugs
      • Dupixent
      • APT-1011
      • Lirentelimab (AK002)
      • Cendakimab
      • Etrasimod
      • TAK-721
      • Omilancor (BT-11)
  • Global Eosinophilic Esophagitis Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Eosinophilic Esophagitis Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • GlaxoSmithKline plc*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Ellodi Pharmaceuticals
    • EsoCap AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Limited
    • Sun Pharmaceutical Industries Limited
    • AstraZeneca Plc
    • Sanofi S.A.
    • Arena Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Revolo Biotherapeutics
    • Allakos Inc.
    • Bristol-Myers Squibb Co
    • Calypso Biotech
    • DBV Technologies
    • Landos Biopharma, Inc.
    • Glenmark Pharmaceuticals
    • Alkem Laboratories Ltd.
    • Quorum Innovations LLC
    • Dr. Falk Pharma GmbH

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global eosinophilic esophagitis market is estimated to be valued at US$ 138.4 million in 2021 and is expected to exhibit a CAGR of 33.3% between 2021 and 2028.
Factors such as increasing awareness programs for Eosinophil-associated disorders are projected to boost the market growth over the forecast period.
The proton pump inhibitor (PPI) segment is expected to hold a major market share of the market in 2021.
The major factor hampering the market growth includes stringent regulatory requirements.
Major players operating in the market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo